Cleveland Biolabs (CBLI) Reports Q1 Loss of $1.14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cleveland BioLabs Reports First Quarter 2015 Financial Results and Development Progress
May 6, 2015 7:30 AM EDTBUFFALO, NY -- (Marketwired) -- 05/06/15 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2015.
Cleveland BioLabs reported a $3.7 million net loss for the first quarter of 2015, or $1.14 per share, compared to a net loss of $1.9 million, or $0.63 per share, for the same period in 2014. The increase of $1.8 million or 95% in net loss was attributable to a $2.1 million income reduction from the period-to-period change in warrant liability, offset by $0.3 million in other reduced expenditures primarily related to reduced research activity for... More
Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
May 5, 2015 7:30 AM EDTBUFFALO, NY -- (Marketwired) -- 05/05/15 -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Langdon L. Miller, M.D., as President and Chief Medical Officer, effective immediately.
Dr. Miller has served as a strategic medical advisor to Cleveland BioLabs since February 2014. He has more than 20 years of experience in the design and conduct of translational and clinical drug development programs in oncology (both in hematological and solid tumors) and orphan diseases. Dr. Miller has worked in all phases of drug development, from first-in-human studies through pivotal registration-directed trials... More
